| Hazard Information | Back Directory | [Uses]
HMC-B17 is a selective, orally bioavailable HPK1 inhibitor (IC50 = 1.39 nM) that potentiates anti-PD-L1 efficacy. HMC-B17 potently enhances the IL-2 secretion in Jurkat cells (EC50 = 11.56 nM). HMC-B17 can be used for the research of cancer[1]. | [References]
[1] Zeng S, et al. Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody. Eur J Med Chem. 2024 Mar 5;267:116206. DOI:10.1016/j.ejmech.2024.116206 |
|
|